Latest:

Fat Pitch Financials

Special situation stocks and value investing

Stock Quote

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lineage Cell Therapeutics Inc (NY: LCTX )

1.180 UNCHANGED
Streaming Delayed Price Updated: 8:00 PM EDT, Sep 25, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lineage Cell Therapeutics Inc

< Previous 1 2 3 4 5 Next >
Lineage Reports Third Quarter 2021 Financial Results and Highlights Progress From Clinical Cell Therapy Programs
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics to Report Third Quarter 2021 Financial Results and Provide Business Update on November 10, 2021
From Lineage Cell Therapeutics, Inc.
Via Business Wire
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... 
Via Benzinga
Exposures Product Safety
OpRegen® Data Update to Be Featured at 2021 American Academy of Ophthalmology Annual Meeting in Presentation by Michael S. Ip, M.D.
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage, Pioneering a New Branch of Medicine — OpRegen Continues to Show Promising Results in Dry AMD with Geographic Atrophy
Photo by Daniil Kuželev on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial... 
Via Benzinga
Lineage to Be Featured in B. Riley Securities Fall 2021 “Growth Biotech Best Ideas” Virtual Series on October 18, 2021
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics Earnings Perspective: Return On Capital Employed
Lineage Cell Therapeutics (AMEX:LCTX) brought in sales totaling $512.00 thousand during Q2 according to data provided by Benzinga Pro. However, earnings decreased 0.43%, resulting... 
Via Benzinga
Lineage to Present at the 2021 Cantor Virtual Global Healthcare Conference on September 27, 2021
From Lineage Cell Therapeutics
Via Business Wire
Promising New OpRegen® Clinical Data Featured at 54th Annual Retina Society Meeting in Podium Presentation by Christopher D. Riemann, M.D.
From Lineage Cell Therapeutics, Inc.
Via Business Wire
38 Stocks Moving In Wednesday's Mid-Day Session
Gainers Indaptus Therapeutics, Inc. (NASDAQ: INDP) shares jumped 177.2% to $19.60 after the company announced the United States Patent and Trademark Office has issued a notice of... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 29) Acceleron Pharma Inc. (... 
Via Benzinga
Exposures COVID-19
53 Biggest Movers From Yesterday
Gainers DICE Therapeutics, Inc. (NASDAQ: DICE) shares surged 117% to settle at $36.89 on Wednesday as the company priced its IPO at $17 per share. PROCEPT BioRobotics Corporation... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
Data From Ongoing Clinical Trial Continues to Demonstrate a Single Administration of OpRegen® Can Provide Anatomical and Functional Improvements in Patients With Dry AMD With Geographic Atrophy
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Opregen® Data Update Will Be Featured at 54th Annual Retina Society Meeting in Podium Presentation by Christopher D. Riemann, M.D.
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Announces Appointment of General Counsel
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics, Inc. (LCTX) Q2 2021 Earnings Call Transcript
LCTX earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Lineage Reports Second Quarter 2021 Financial Results and Highlights Additional Progress From Clinical Cell Therapy Programs
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Age-Related Macular Degeneration: What is Dry AMD, and How is Lineage Cell Therapeutics Changing the Game?
Image by Rudy and Peter Skitterians from Pixabay Age-related macular degeneration (AMD) is a disease originating in the retina, which may worsen over time, according to... 
Via Benzinga
Lineage to Present at the H.C. Wainwright Ophthalmology Conference on August 17, 2021
From Lineage Cell Therapeutics, Inc.
Via Business Wire
The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11) Adagio Therapeutics, Inc. (... 
Via Benzinga
Exposures Product Safety
Lineage Cell Therapeutics to Report Second Quarter 2021 Financial Results and Provide Business Update on August 12, 2021
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell's Dry AMD Gene Therapy Demonstrate Functional, Anatomical Improvements
Lineage Cell Therapeutics Inc (NYSE: LCTX) reported updated interim results from its Phase 1/2a study of its lead product candidate, OpRegen cell therapy for dry... 
Via Benzinga
OpRegen® Clinical Data Continues to Demonstrate Functional and Anatomical Improvements in Patients With Dry AMD With Geographic Atrophy
From Lineage Cell Therapeutics, Inc.
Via Business Wire
OpRegen® Data Update to Be Featured at 54th Annual Retina Society Meeting in Podium Presentation by Christopher D. Riemann, M.D.
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics Joins Russell 3000® and Russell Microcap® Indexes
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage’s OPC1 Cell Therapy for the Treatment of Spinal Cord Injury to Return to Clinical Testing
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Inks Option Agreement With Amasa Therapeutics For HyStem
Lineage Cell Therapeutics Inc (NYSE: LCTX) has granted an exclusive option to Amasa Therapeutics Inc to acquire an exclusive, royalty-bearing license to use its... 
Via Benzinga
Lineage Announces Exclusive Option Agreement With Amasa Therapeutics for Supply and Use of Clinical-Grade Hystem®
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics Announces Kevin L. Cook to Join as Chief Financial Officer
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics to Present at Raymond James 2021 Human Health Innovation Conference on June 22, 2021
From Lineage Cell Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.